Imclone's board said Bristol-Myers Squibb's $60-per-share takeover bid appeared too low but added that it would still study the unsolicited offer. Investor Carl Icahn, chairman of Imclone, said the bid "greatly undervalues" the company[...]
Yahoo (YHOO) is holding its annual meeting today, and with the threat of Carl Icahn's dissident board slate removed, all that's left is some shouting. Here in a nutshell is what they will be shouting about: Price of Yahoo's shares on January 31, before the Microsoft (MSFT) $31 bid: $19.18. [...]
A few quick links to get people going "hmmm" on this foggy Friday (here in San Diego, anyway): Resurgent bearish macro hedge funds have people seeing next Soros (Bloomberg) Copper thieves cause delay in cancer surgery (LA Times) Live ATask updates from YHOO annual meeting (Twitter) Nice new realtime news [...]
Bristol-Myers Squibb on Thursday became the latest big pharma company to bid for a smaller rival. It offered $60 per share for ImClone Systems, the New York biotech company chaired by activist investor Carl Icahn[...]
London-based hedge-fund manager RAB Capital PLC has nearly halved its provision for bonuses, following an 18.1% fall in assets in the first half of this year and a 30.4% decline in the size of its flagship fund. RAB Capital said it did not expect respite from the "challenging" market environment [...]
Company News: > KeyCorp downgraded. Article > Deutsche Bank takes another $3.6 billion in writedowns. Article > Can these banks bounce back? Article > American Express settlement leads to MasterCard loss. Article > Alan Schwartz to leave JPMorgan, where will he land? Article > Fitch downgrades FGIC. Article > More on [...]
Is it just me or does the dire situation of Grizabella the Glamour Cat in the musical "Cats" remind you a little bit too much of what has been going on with Yahoo (YHOO) and its CEO Jerry Yang over the last year? Thus, BoomTown has decided to make that [...]
